Abstract

Towards Glioma Intra-operative Photodynamic Therapy: Targeted Photo-active Nanoparticles in a Brain Tumor Window Model

Highlights

  • Primary malignant brain tumors and especially Glioblastoma multiforma represent one of the most formidable challenges facing oncologists today

  • Modification of the surface by the attachment of polyethylene glycol (PEG), and/or by targeting ligands, had no significant effect on the size of particles in solution. These nanoparticles fall within the optimal range of 10-100 nm which has proved to be very effective for in vivo applications; this is because nanoparticles greater than 10 nm have the ability to avoid clearance by the kidney, allowing for prolonged and elevated circulatory levels, and nanoparticles smaller than 100 nm avoid entrapment by phagocytes [54,55]

  • The F3-modified nanoparticles have a surface charge of +12 (± 1) mV, whereas the non-targeted nanoparticles have a charge of + 2 (± 1) mV, in comparison to the unmodified nanoparticles that have free amine groups on the surface, having a charge of +14 (± 3) mV

Read more

Summary

Introduction

Primary malignant brain tumors and especially Glioblastoma multiforma represent one of the most formidable challenges facing oncologists today The propensity of these tumors to infiltrate normal, functioning brain complicates regional treatments like surgery and radiation therapy. The relative resistance of the tumor cells to cytotoxic agents and difficulty in delivery of these agents across the blood brain barrier hamper efforts to kill individual tumor cells [1,2,3] These tumors, once discovered, inexorably progress, causing death, usually less than two years after diagnosis [1]. Converging lines of evidence suggest that maximal surgical removal of the tumor affords a survival advantage Immunological therapies such as dendritic cell vaccines have surfaced, these modalities are still in early phase studies. All these approaches remain promises for a not yet achieved rosier future

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.